Evidence map›Paper›PMID 30443716›Full record

ArticleDer Urologe. Ausg. A2018

[Vaccination: Protection for boys against genital warts and cancer via human papillomavirus infection].

W Bühmann

Abstract read
PubMed Publisher
In one paragraph

Article in Der Urologe. Ausg. A, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. [Additional comments on HPV vaccination for boys].Urologie (Heidelberg, Germany) · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

W Bühmann, Terpstig 55, 25980, Sylt OT Morsum, Deutschland. post@urologie-sylt.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccination qualifies as the most effective medical procedure worldwide. Using the example of human papillomavirus(HPV)-associated benign and malignant diseases, the incidence, diagnostics, treatment, particularly however, the option of sustainable elimination of all these entities by achieving herd immunity by a gender balanced inoculation quota of 80% at the age of 9-17 years are shown.

Indexed as

Condylomata AcuminataGenital Neoplasms, MalePapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesAdolescentChildHumansMaleVaccinationPapillomavirus VaccinesCondylomaGender-equal vaccinationNeoplasmsPrimary preventionSexually transmitted infections

Identifiers

PMID30443716

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.